Rituximab

Overview

Rituximab is a chimeric monoclonal antibody that targets the CD20 antigen expressed on B-cells. Originally developed for the treatment of B-cell lymphomas, rituximab has become one of the most widely used therapeutic antibodies in medicine, with applications extending from hematological malignancies to a broad range of autoimmune disorders["@cd20_biology"].

In the context of neurodegenerative diseases, rituximab represents an attempt to target the B-cell component of the immune system that may contribute to neurodegeneration in certain conditions. By depleting CD20-positive B-cells, the antibody reduces autoantibody production, antigen presentation, and inflammatory cytokine release—all mechanisms that may be relevant in conditions where immune dysregulation contributes to neuronal damage.

Mechanism of Action

Rituximab exerts its therapeutic effects through multiple complementary mechanisms[@b_cell_depletion]:

CD20 Targeting

Overview

Rituximab is a chimeric monoclonal antibody that targets the CD20 antigen expressed on B-cells. Originally developed for the treatment of B-cell lymphomas, rituximab has become one of the most widely used therapeutic antibodies in medicine, with applications extending from hematological malignancies to a broad range of autoimmune disorders["@cd20_biology"].

In the context of neurodegenerative diseases, rituximab represents an attempt to target the B-cell component of the immune system that may contribute to neurodegeneration in certain conditions. By depleting CD20-positive B-cells, the antibody reduces autoantibody production, antigen presentation, and inflammatory cytokine release—all mechanisms that may be relevant in conditions where immune dysregulation contributes to neuronal damage.

Mechanism of Action

Rituximab exerts its therapeutic effects through multiple complementary mechanisms[@b_cell_depletion]:

CD20 Targeting

CD20 Expression:

• CD20 is a surface antigen expressed on most mature B-cells
• Expressed from pre-B-cell stage through mature B-cells
• Not expressed on plasma cells (which produce antibodies)
• This pattern allows B-cell depletion while sparing antibody-producing plasma cells

• Chimeric antibody with murine variable regions and human IgG1 Fc
• Designed for optimal effector function
• Mediates complement activation and antibody-dependent cellular cytotoxicity

Complement-Dependent Cytotoxicity (CDC)

Mechanism:

• Rituximab bound to CD20 activates the classical complement pathway
• Formation of membrane attack complex (MAC)
• Direct lysis of B-cells
• Particularly effective against cells with high CD20 density

Antibody-Dependent Cellular Cytotoxicity (ADCC)

Mechanism:

• Fc portion of rituximab engages Fcγ receptors on natural killer cells, macrophages, and neutrophils
• These effector cells destroy rituximab-coated B-cells
• ADCC is a major mechanism of B-cell depletion in vivo

Direct Effects on B-cell Function

Apoptosis Induction:

• Cross-linking of CD20 by rituximab can directly induce apoptosis
• Contributes to B-cell depletion independent of immune effector mechanisms

• May modulate B-cell receptor signaling
• Reduces B-cell activation and proliferation

Clinical Applications in Neurodegeneration

Multiple System Atrophy

MSA is a rapidly progressive neurodegenerative disorder characterized by parkinsonian, cerebellar, and autonomic features. Evidence of B-cell involvement has motivated investigation of rituximab[@krismer2021]:

Rationale:

• B-cells have been implicated in the pathogenesis of MSA
• Autoantibodies against neural antigens detected in some patients
• Glial pathology may have immune components
• Rationale for B-cell targeting

• Phase II trials have investigated rituximab in MSA
• Some studies showed benefit in motor symptoms
• Results have been variable across studies
• Larger controlled trials are needed

• May slow disease progression in some patients
• Effects more pronounced in early disease stages
• Not yet established as standard treatment

Progressive Supranuclear Palsy

PSP is a tauopathy characterized by tau accumulation in subcortical and brainstem regions. While primarily a proteinopathy, immune mechanisms may contribute[@holmy2019]:

Rationale:

• Microglial activation documented in PSP brains
• Possible B-cell involvement in disease pathogenesis
• Theoretical basis for immune modulation

• Limited trials of rituximab in PSP
• Mixed results across studies
• Some patients showed slowed progression
• Insufficient evidence for routine use

Amyotrophic Lateral Sclerosis

ALS involves progressive loss of motor neurons. Immune dysregulation, including potential autoimmune components, has been implicated[@miller2020]:

Rationale:

• T-cell abnormalities in ALS
• Potential for autoimmune-mediated motor neuron damage
• Microglial activation contributes to neurodegeneration

• Trials of rituximab in ALS have been conducted
• Results have been generally negative
• No clear benefit demonstrated
• Not used clinically for ALS

Paraneoplastic Neurological Disorders

Rituximab is established in the treatment of paraneoplastic neurological syndromes:

Conditions Treated:

• Paraneoplastic cerebellar degeneration (anti-Yo, anti-Hu)
• Limbic encephalitis (anti-Ma2, anti-Hu)
• Paraneoplastic encephalomyelitis
• Opsoclonus-myoclonus syndrome

• Multiple case series demonstrate efficacy
• Often used in combination with other immunotherapies
• Particularly useful when antibodies target intracellular antigens (where plasma cell-targeting therapies are less effective)

• Variable depending on antibody type and timing
• Earlier treatment generally produces better outcomes
• May require repeated dosing

Autoimmune Encephalitis

Rituximab has become a cornerstone treatment for autoimmune encephalitis with surface antibodies:

First-Line Treatment:

• Anti-NMDA receptor encephalitis
• LGI1 encephalitis
• CASPR2 encephalitis
• Other surface antibody syndromes

• Highly effective in preventing relapse
• Superior to steroids alone in some studies
• Often used after first-line (steroids, IVIG, plasma exchange) fails
• May be used upfront in severe cases

• Standard: 375 mg/m² weekly for 4 weeks
• Alternative: 1 g on day 1 and day 15
• Re-dosing for relapse prevention in some cases

Other Neurological Applications

Myasthenia Gravis:

• Used in refractory cases
• Particularly effective in anti-MuSK positive MG
• Reduces relapse rate

• Second-line treatment when conventional therapies fail
• Effective in some patients

• Not FDA-approved but used off-label in progressive forms
• Not as effective as for other autoimmune conditions

Pharmacokinetics and Administration

Pharmacokinetic Properties

• Half-life: Approximately 21 days (range 15-30 days)
• Volume of distribution: Similar to plasma volume
• Clearance: Through reticuloendothelial system

Administration Protocol

Standard Dosing (for autoimmune conditions):

• 375 mg/m² weekly for 4 weeks
• Or 1 g on day 1 and day 15
• Premedication with antihistamine, acetaminophen, and often corticosteroids

• Diphenhydramine 25-50 mg
• Acetaminophen 650-1000 mg
• Methylprednisolone 100 mg (in many protocols)
• Reduces infusion reaction risk

B-cell Depletion Kinetics

Timeline:

• Peripheral B-cell depletion begins within 2-3 weeks
• Nadir typically achieved by 1-2 months
• B-cells remain depleted for 6-12 months
• Reconstitution begins from bone marrow progenitors

• CD19+ B-cell counts can be monitored
• Useful for timing re-treatment if needed

Adverse Effects and Safety

Infusion-Related Reactions

Frequency: Most common adverse effect, especially with first infusion

Symptoms:

• Fever and chills
• Hypotension or hypertension
• Bronchospasm
• Nausea and vomiting
• Headache
• Rash

• Premedication as described
• Slower infusion rate for reactions
• Stop infusion for severe reactions
• Most reactions are manageable

Infectious Complications

Increased Infection Risk:

• Overall infection risk moderately increased
• Particularly respiratory and urinary tract infections

• Screen for HBV before treatment
• Prophylaxis for high-risk patients
• Can cause severe hepatitis if reactivated

• Rare but serious risk
• John Cunningham virus reactivation
• Risk higher in combination with other immunosuppressants
• Often fatal or severely disabling
• Requires prompt recognition if symptoms develop

Other Adverse Effects

Hypogammaglobulinemia:

• Can develop after repeated cycles
• May increase infection risk
• May require IVIG replacement in severe cases

• Rare cardiac arrhythmias reported
• Exacerbation of pre-existing heart failure
• Most relevant in patients with underlying cardiac disease

• Fatigue
• Musculoskeletal pain
• Rare cytopenias
• Tumor lysis syndrome (rare)

Contraindications

• Active severe infection
• Known hypersensitivity to rituximab
• Severe heart failure
• Pregnancy (relative, use only if benefit outweighs risk)
• Active malignancy (relative)

Comparison with Other B-cell Targeting Therapies

| Agent | Target | Mechanism | Neurological Use |
|-------|--------|-----------|------------------|
| Rituximab | CD20 | Depletes B-cells | AE, CIDP, MG, PND |
| Ocrelizumab | CD20 | Depletes B-cells | MS (approved) |
| Ofatumumab | CD20 | Depletes B-cells | MS (approved) |
| Belimumab | BLyS | Inhibits B-cell survival | Lupus (not neuro) |
| Eculizumab | C5 | Complement inhibition | NMOSD (approved) |

Future Directions

New CD20 Antibodies

Ocrelizumab:

• Humanized anti-CD20
• Approved for multiple sclerosis
• Less immunogenic than rituximab

• Fully human anti-CD20
• Subcutaneous administration
• Approved for MS

• Glycoengineered for enhanced ADCC
• Being studied in various autoimmune conditions

Combination Approaches

• Combining rituximab with other immunomodulatory agents
• Sequential therapies targeting different immune pathways
• Integration with conventional treatments

See Also

• [Multiple System Atrophy](/diseases/multiple-system-atrophy)
• [Progressive Supranuclear Palsy](/diseases/progressive-supranuclear-palsy)
• [Autoimmune Encephalitis](/diseases/autoimmune-encephalitis)
• [Myasthenia Gravis](/diseases/myasthenia-gravis)
• [B-cell Biology](/mechanisms/b-cell-neuroinflammation)
• [Neuroinflammation](/mechanisms/neuroinflammation-parkinsons)

References